Eton Pharmaceuticals, Inc.(ETON)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #364 of 2,961 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ETON Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Eton Pharmaceuticals, Inc. (ETON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ETON at 67.5/100 on a 32-signal composite quality model, placing it at rank #364 of 2,961 stocks — the top 25% of the AI-ranked universe. ETON scores in the top quartile across revenue growth (95.5), balance sheet strength (88.4), profitability (75.3). Areas of concern include revenue scale (16.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Eton Pharmaceuticals, Inc. reports quarterly revenue of $37.6M, net income of $11.6M, free cash flow of $7.3M. Top institutional holders of ETON by reported 13-F value include Opaleye Management, EcoR1 Capital, BlackRock, based on the most recent SEC filings. ETON trades on the Nasdaq exchange and files with the SEC under CIK 1710340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ETON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eton Pharmaceuticals, Inc. directly from SEC EDGAR. Eton Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 43 and 68 since 2024, currently 67.5 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving ETON's Business? Latest 10-Q Breakdown
AI-extracted from Eton Pharmaceuticals, Inc.'s 10-Q filed 2026-08-13 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Eton swung to $12.8M operating income from a $1.5M operating loss a year ago as Q2 total revenue nearly doubled to $37.6M, aided by growth in INCRELEX, GALZIN and Carglumic Acid plus newly acquired HEMANGEOL sales.
Biggest Revenue Drivers
Increase was primarily the result of increased sales of INCRELEX, GALZIN, Carglumic Acid and the addition of HEMANGEOL product sales in the current period.
No licensing revenue was recognized in either three-month period.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q2 2026
$37.6M
Net Income
Q2 2026
$11.6M
Free Cash Flow
Q2 2026
$7.3M
ROIC
Q2 2026
68.7%
D/E Ratio
Q2 2026
0.60
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+104.9% YoYNet Income
-20.4% YoYOperating Income
+67.5% YoYTotal Assets
+21.0% YoYTotal Debt
+32.0% YoYOp. Cash Flow
+986.1% YoYFree Cash Flow
+980.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $80.0M +104.9% | $39.0M +23.3% | $31.6M +48.9% | $21.3M -2.7% | $21.8M +55879.5% | $39.0K |
| Net Income | $-4.6M -20.4% | $-3.8M -308.4% | $-936.0K +89.6% | $-9.0M -361.4% | $-2.0M +93.0% | $-28.0M |
| Operating Income | $-844.0K +67.5% | $-2.6M -117.9% | $-1.2M +85.6% | $-8.3M -452.5% | $-1.5M +94.5% | $-27.1M |
| Total Assets | $92.1M +21.0% | $76.1M +139.8% | $31.7M +26.8% | $25.0M -8.9% | $27.5M +4.4% | $26.3M |
| Total Debt | $39.3M +32.0% | $29.8M +454.1% | $5.4M -16.2% | $6.4M -3.9% | $6.7M +2.3% | $6.5M |
| Operating Cash Flow | $10.5M +986.1% | $969.0K -85.8% | $6.8M +41.4% | $4.8M +202.1% | $-4.7M +78.9% | $-22.3M |
| Free Cash Flow | $10.2M +980.7% | $943.0K -86.2% | $6.8M +42.5% | $4.8M +201.1% | $-4.7M +78.9% | $-22.4M |
Get alerted when ETON's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Eton Pharmaceuticals, Inc. including:
Top Institutional Holders of ETON
Opaleye Management Inc.
$103.5M2,860,000 shEcoR1 Capital, LLC
$78.6M2,171,938 shBlackRock, Inc.
$68.6M1,895,833 shNantahala Capital Management, LLC
$42.6M1,175,951 shVANGUARD CAPITAL MANAGEMENT LLC
$35.4M976,570 shMORGAN STANLEY
$27.8M767,972 shSTATE STREET CORP
$25.4M701,786 shGEODE CAPITAL MANAGEMENT, LLC
$23.6M652,303 shOBERWEIS ASSET MANAGEMENT INC/
$18.2M501,600 shNational Philanthropic Trust
$17.8M492,112 sh
| Fund | Value | Shares |
|---|---|---|
| Opaleye Management Inc. | $103.5M | 2,860,000 |
| EcoR1 Capital, LLC | $78.6M | 2,171,938 |
| BlackRock, Inc. | $68.6M | 1,895,833 |
| Nantahala Capital Management, LLC | $42.6M | 1,175,951 |
| VANGUARD CAPITAL MANAGEMENT LLC | $35.4M | 976,570 |
| MORGAN STANLEY | $27.8M | 767,972 |
| STATE STREET CORP | $25.4M | 701,786 |
| GEODE CAPITAL MANAGEMENT, LLC | $23.6M | 652,303 |
| OBERWEIS ASSET MANAGEMENT INC/ | $18.2M | 501,600 |
| National Philanthropic Trust | $17.8M | 492,112 |
Companies Similar to ETON
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ZEVRA THERAPEUTICS, INC.
Arcutis Biotherapeutics, Inc.
ANI PHARMACEUTICALS INC
Aurinia Pharmaceuticals Inc.
Fortress Biotech, Inc.
MeiraGTx Holdings plc
VIEMED HEALTHCARE, INC.
Liquidia Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ETON on your watchlist
Track score changes the day Eton Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ETON a good stock to buy?
13F Pro's AI-powered analysis of Eton Pharmaceuticals, Inc. (ETON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ETON are available on the ETON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ETON is classified as a small company.
Which hedge funds own ETON?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ETON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eton Pharmaceuticals, Inc.'s investment landscape.